SpliceBio is a genetic medicines company harnessing its proprietary Protein Splicing platform to develop the next generation of gene therapies. The platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research.
| Ownership Private Company |
| Funding $2.05 m |
SpliceBio is a genetic medicines company that harnesses a proprietary Protein Splicing platform to develop the next generation of gene therapies, based on technology from Princeton University.
Biotechnology research and development focusing on gene therapies using a proprietary Protein Splicing platform.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with SpliceBio